Tower Research Capital (TRC)’s China SXT Pharmaceuticals SXTC Stock Holding History

Tower Research Capital (TRC)’s Portfolio SXTC Stock Details SXTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-12	Closed	-$2.92K	–	5548
2025 Q4	$2.92K	Sell	12 -7	-37%	-$1.52K	﹤0.01%	4450
2025 Q3	$4.52K	Buy	19 +18	+1,800%	+$4.45K	﹤0.01%	4337
2025 Q2	$261	Buy	+1	New	+$284	﹤0.01%	5076

Other funds holding SXTC

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

CIAM

Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Tower Research Capital (TRC)'s SXTC Position: Q1 2026 in Review

Tower Research Capital (TRC) sold out of China SXT Pharmaceuticals (SXTC) in Q1 2026, closing a stake of 12 shares — an estimated $2.92K sold.

Tower Research Capital (TRC) first reported a position in SXTC in Q2 2025 and held it in 3 quarters. The position peaked at $4.52K in Q3 2025. 4 funds tracked by Wall St. Rank hold SXTC as of Q1 2026.

Tower Research Capital (TRC) reported no remaining China SXT Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Tower Research Capital (TRC) sold 12 China SXT Pharmaceuticals shares in Q1 2026, an estimated $2.92K.
Tower Research Capital (TRC) first reported a position in China SXT Pharmaceuticals in Q2 2025 and held it in 3 quarters.
Tower Research Capital (TRC)'s China SXT Pharmaceuticals position peaked at $4.52K in Q3 2025.
4 funds tracked by Wall St. Rank held China SXT Pharmaceuticals as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.